For a day trader you are probably right as the gamble due to the extreme manipulation. For the patient investor I have to disagree.
Any in doubt simply look at Biosante' market cap and pipeline read about it and understand it. Then start looking at the competitor's pipelines and stop when you come close to a company with a similar diversified pipeline. That is your fair market value. You will notice that you have to climb a long way to find a company with a similarly diversified pipeline.
The probability of going to $2 in 2 weeks is far greater then going to $0.50 and staying for 3 months.
I have added a post by NutsyProfessor which must be considered before writing off BPAX.
Here's the real scope on LibiGel bashers:
There are millions of OFF-LABEL testosterone prescriptions currently being given by doctors to address FSD!!! The FDA wants to solve this problem!!!
LibiGel will be the first of it's kind for this treatment that will not only complete a Safety Trail under an FDA SPA but, as it turns out, LibiGel is actually REDUCING the number of CV events vs placebo.
The FDA will aprove LibiGel to treat FSD for the following reasons REGARDLESS of efficacy:
1) LibiGel will have completed a safety trial under an FDA SPA.
2) LibiGel will address the off-label usage issue.
3) LibiGel REDUCES CV events.
This is a win-win-win for all: the FDA, Doctor's and patients.
Like it or not LibiGel will proceed, an NDA will be submitted to the FDA, and it will be approved.
In addition, BPAX still owns the full rights to Bio-t-Gel and Elestrin. There is a world outside the US and the growth potential is huge.
By partnering they have found a way to move their diverse pipeline forward. Instead of putting their eggs in one basket and going it alone they have chosen to spread out the risk. In time this model will create a very good revenue stream as more products get approved. This allows Biosante to concentrate on their business strength R&D.
If you are shorting this stock any piece of positive news could derail your plans.
- Libigel FDA meeting results,
- Elestrin and Bio-t-gel worldwide distribution deals at a greater
royalty rate
- Partnering for a Phase III cancer trial or Pill plus trial
- Even the sale of the company or one of its products.
- The realization of the rest of the investment community as to
how undervalued the stock is.
Just keeping it real. By doing my research, I suggest others do the same.
AI
